Cargando…

Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?

SIMPLE SUMMARY: Neuroendocrine carcinomas (NECs) represent the most aggressive subgroup of neuroendocrine neoplasms. Around 90% of NECs arise from the lung. The minority of NECs originating outside of the lung are called extra-pulmonary (EP)-NECs. Most patients with EP-NECs are diagnosed at an advan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frizziero, Melissa, Durand, Alice, Taboada, Rodrigo G., Zaninotto, Elisa, Luchini, Claudio, Chakrabarty, Bipasha, Hervieu, Valérie, Claro, Laura C. L., Zhou, Cong, Cingarlini, Sara, Milella, Michele, Walter, Thomas, Riechelmann, Rachel S., Lamarca, Angela, Hubner, Richard A., Mansoor, Wasat, Valle, Juan W., McNamara, Mairéad G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392018/ https://www.ncbi.nlm.nih.gov/pubmed/34439308 http://dx.doi.org/10.3390/cancers13164152

Ejemplares similares

Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis
por: Frizziero, Melissa, et al.
Publicado: (2020)

The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases
por: Kapacee, Zainul-Abedin, et al.
Publicado: (2022)

Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice
por: Lamarca, Angela, et al.
Publicado: (2022)

Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours
por: Chiramel, Jaseela, et al.
Publicado: (2020)

Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres
por: Frizziero, Melissa, et al.
Publicado: (2019)

PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours
por: Lamarca, Angela, et al.
Publicado: (2018)

Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis
por: McNamara, Mairéad G., et al.
Publicado: (2020)

Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes
por: Taboada, Rodrigo G, et al.
Publicado: (2022)

Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice
por: Lamarca, Angela, et al.
Publicado: (2019)

Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma
por: Weaver, Jamie M. J., et al.
Publicado: (2023)

The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms
por: Shah, Dinakshi, et al.
Publicado: (2021)

Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter
por: Exarchou, Klaire, et al.
Publicado: (2022)

Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
por: Megdanova-Chipeva, Vera G., et al.
Publicado: (2020)

Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer
por: Pihlak, Rille, et al.
Publicado: (2023)

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma
por: McNamara, Mairéad G., et al.
Publicado: (2023)

Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review
por: Robinson, Matthew D., et al.
Publicado: (2023)

Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours
por: Lewis, Alexandra R, et al.
Publicado: (2018)

The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer
por: Abdul Rahman, Rozana, et al.
Publicado: (2021)

NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)
por: Craig, Zoe, et al.
Publicado: (2020)

Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Chiramel, Jaseela, et al.
Publicado: (2017)

Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review
por: Shotton, Rohan, et al.
Publicado: (2021)

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
por: Foy, Victoria, et al.
Publicado: (2023)

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
por: Galdy, Salvatore, et al.
Publicado: (2016)

Targeted Therapies for Perihilar Cholangiocarcinoma
por: Gray, Simon, et al.
Publicado: (2022)

Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
por: Saavedra, Cristina, et al.
Publicado: (2019)

Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
por: Luchini, Claudio, et al.
Publicado: (2021)

Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma
por: Najran, Pavan, et al.
Publicado: (2017)

Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers
por: Lamarca, Angela, et al.
Publicado: (2020)

Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes
por: Gray, Simon, et al.
Publicado: (2023)

Clinical and Pathologic Characteristics of Pulmonary Carcinoid Tumors in Central and Peripheral Locations
por: Papaxoinis, George, et al.
Publicado: (2018)

Diagnostic and Management Pathways for Pulmonary Carcinoid Tumours in the United Kingdom: Results from the National Lung Neuroendocrine Tumour Pathway Project
por: Mansoor, Wasat, et al.
Publicado: (2020)

The Impact of (68)Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours
por: Cuthbertson, Daniel J., et al.
Publicado: (2021)

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
por: Lamarca, Angela, et al.
Publicado: (2018)

Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice
por: Fulton, Alexander JP, et al.
Publicado: (2019)

Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocol
por: Carnie, Lindsay E, et al.
Publicado: (2021)

Germline mutations in pancreatic cancer and potential new therapeutic options
por: Pihlak, Rille, et al.
Publicado: (2017)

The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC)
por: Wheatley, Roseanna C., et al.
Publicado: (2022)

Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary
por: Conway, Alicia-Marie, et al.
Publicado: (2022)

Patients Undergoing Systemic Anti-Cancer Therapy Who Require Surgical Intervention: What Surgeons Need to Know
por: Robinson, Matthew D., et al.
Publicado: (2023)

Biliary tract cancers: current knowledge, clinical candidates and future challenges
por: Tariq, Noor-ul-Ain, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0shts50t344vq90vik1hjm4ec2